Rula vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
Mental health marketplace connecting patients with in-network therapists and psychiatrists, Los Angeles CA, raised $65M+. Insurance-covered access in all 50 states.
About
Rula is a Los Angeles, California-based mental health marketplace founded in 2019 that connects patients with in-network licensed therapists and psychiatrists through an online directory and matching platform. The company has raised over $65 million and has built insurance coverage across all 50 US states, making it one of the broadest-access in-network therapy platforms in the country. Rula handles provider credentialing, insurance contracting, billing, and claims processing on behalf of its network clinicians.\n\nRula's marketplace allows patients to search for therapists and psychiatrists by specialty, insurance, location, language, and availability, with real-time availability shown and direct booking enabled. The platform is designed to reduce the common friction points in finding in-network mental health care: lengthy wait times, confusing insurance directory inaccuracies, and billing surprises. Rula verifies insurance eligibility before the first appointment and provides upfront cost estimates so patients know their expected out-of-pocket responsibility.\n\nThe company has focused heavily on therapist experience and provider satisfaction, offering competitive reimbursement rates, automated billing, flexible scheduling, and dedicated support to attract and retain high-quality clinicians. Rula competes with Headway, Alma, and Grow Therapy in the therapist marketplace and infrastructure segment. With its 50-state insurance footprint and consumer-friendly search experience, Rula is positioned as an accessible alternative to the fragmented and often outdated directories maintained by health plans.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.